Skip to main content

Lantus Disease Interactions

There are 3 disease interactions with Lantus (insulin glargine).

Moderate

Insulin (applies to Lantus) renal/liver disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Insulin requirements may be diminished in patients with renal or hepatic impairment due to reduced insulin metabolism and, in the latter case, also to reduced capacity for gluconeogenesis. Lower initial dosages may be appropriate, with careful monitoring of plasma glucose levels and dosing adjustments.

References

  1. "Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.
  2. "Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals PROD (2001):
  3. "Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc (2022):
  4. "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals (2004):
  5. "Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc (2005):
  6. "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation (2014):
  7. "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc (2015):
View all 7 references
Moderate

Insulin- hypokalemia

Moderate Potential Hazard, Moderate plausibility.

Hypokalemia may commonly occur during treatment with insulin. Use with caution in patients who may be particularly at risk of developing hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).

References

  1. "Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.
  2. "Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals PROD (2001):
  3. "Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc (2022):
  4. "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals (2004):
  5. "Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc (2005):
  6. "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation (2014):
  7. "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc (2015):
View all 7 references
Moderate

Insulin/oral hypoglycemic agents (applies to Lantus) hypoglycemia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Adrenal Insufficiency, Malnourished, Autonomic Neuropathy, Panhypopituitarism, Anorexia/Feeding Problems

Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents. Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.

References

  1. "Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals PROD (2002):
  2. "Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals PROD (2002):
  3. "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.
  4. "Product Information. Micronase (glyburide)." Pharmacia and Upjohn PROD (2002):
  5. "Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.
  6. "Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel PROD (2001):
  7. "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc PROD (2001):
  8. "Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn PROD (2001):
  9. "Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company PROD (2001):
  10. "Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals PROD (2001):
  11. "Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc (2022):
  12. "Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals PROD (2001):
  13. "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals (2004):
  14. "Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc (2005):
  15. "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc (2015):
  16. "Product Information. Glucophage (metFORMIN)." EMD Serono Inc SUPPL-34 (2018):
View all 16 references

Lantus drug interactions

There are 385 drug interactions with Lantus (insulin glargine).

Lantus alcohol/food interactions

There is 1 alcohol/food interaction with Lantus (insulin glargine).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.